Alnylam Pharmaceuticals Inc (ALNY)
Summary
ALNY Chart
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
ALNY Stock Tanks 28% as Q2 Earnings Miss Estimates, '26 Sales View Cut
Alnylam stock plunges after Q2 earnings and revenue miss estimates, while a cut to 2026 product sales guidance overshadows record quarterly Amvuttra sales.
Alnylam Pharmaceuticals Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 1,389 | $561,015.9 | $301,732.47 | -$259,283.43 | -46.22% |
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 132 | $31,596.16 | $27,128.64 | -$4,467.52 | -14.14% |
| LC Lisa Candera CIGNA INVESTMENTS Inc. /NEW | 1,278 | $259,812.89 | $262,654.56 | $2,841.67 | 1.09% |
 Curtis Ellergodt Rothschild Investment LLC | 159 | $72,504 | $35,111.97 | -$37,392.03 | -51.57% |
 Dodge & Cox Dodge & Cox Funds | 1.96M | $280.54M | $437.91M | $157.37M | 56.1% |
Alnylam Pharmaceuticals Inc Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Paul Matteis Stifel | 119.83 | $24,627.48 | $24,627.48 | - | - |
Alnylam Pharmaceuticals Inc (ALNY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alnylam Pharmaceuticals Inc ever had a stock split?
Alnylam Pharmaceuticals Inc Profile
| Biotechnology Industry | Healthcare Sector | Yvonne L. Greenstreet CEO | NASDAQ (NGS) Exchange | 02043Q107 CUSIP |
| US Country | 2,500 Employees | - Last Dividend | - Last Split | 28 May 2004 IPO Date |
Overview
Alnylam Pharmaceuticals, Inc. is a leading biopharmaceutical company that specializes in discovering, developing, and commercializing innovative therapeutics based on ribonucleic acid interference (RNAi). Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam is at the forefront of RNAi technology, employing this revolutionary science to tackle complex diseases at the genetic level. The company's commitment to innovation is underscored by its dynamic pipeline of products and its strategic collaborations with major players in the pharmaceutical industry, such as Regeneron Pharmaceuticals, Inc., Roche, Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. These partnerships aim to expand the potential of RNAi therapy across various diseases, including those affecting the eye, central nervous system (CNS), and more.
Products and Services
- ONPATTRO (patisiran)
Approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults, this product exemplifies Alnylam's commitment to addressing rare diseases with significant unmet needs.
- AMVUTTRA
Also targeting hATTR amyloidosis, AMVUTTRA is specifically approved for treating adults with polyneuropathy, showcasing the company's focused approach on this genetic disorder.
- GIVLAARI (givosiran)
For adults with acute hepatic porphyria (AHP), a rare metabolic disorder, GIVLAARI represents a significant advancement in treatment options, highlighting Alnylam's dedication to tackling challenging hepatic conditions.
- OXLUMO (lumasiran)
This product is designed for the treatment of primary hyperoxaluria type 1 (PH1), a rare genetic disorder, further demonstrating Alnylam's expertise in developing treatments for rare conditions.
- Development Pipeline
- Patisiran - in development for ATTR amyloidosis with cardiomyopathy.
- Cemdisiran - targeted to treat complement-mediated diseases.
- Belcesiran - for the treatment of alpha-1 liver disease.
- Elebsiran - aimed at chronic HBV infection treatment.
- Zilebesiran - under development to treat hypertension, in collaboration with Roche.
- ALN-APP - for Alzheimer's disease and cerebral amyloid angiopathy.
- ALN-HSD - targeted to treat NASH.
- Fitusiran - for the treatment of hemophilia, showcasing Alnylam's expansion into blood disorders.
- Inclisiran - aimed at treating hypercholesterolemia, highlighting Alnylam's foray into cardiovascular diseases.
- Vutrisiran - in phase 3 clinical trial for ATTR amyloidosis, underscoring ongoing commitment to this disease area.
